Gemma N. Jones et al has recently published in the British Journal of Cancer an article revealing pRAD50 (Ser635) as a pharmacodynamic biomarker of ATM (AZD0156) and ATR inhibitors (AZD6738) to treat cancers. doi:10.1038/s41416-018-0286-4

Key sensors of DNA damage such as ATM and ATR are targets of choice for drug discovery. A useful screening method is based on synthetic lethality. The pre-screening can be done on convenient HeLa cells.

In a previous post, I introduced the G-Series Mouse antibody arrays to profile up to 200 mouse proteins using a combination of 5 antibody arrays on glass slide. This new Mouse L2 L-Series (label based antibody array) goes one step further in the number of targets to profile – 500 on one single array – allowing you to work with smaller sample volume. Read more about the technology and its advantages in this post, whether you’re considering using it in your lab, or outsourcing your project to save time & ressources.

RayBiotech , the antibody array specialist, have just released a new, very broad antibody microarray, the L2000 series, for the profiling of 2000 protein targets including metabolic enzymes, structural proteins, and a variety of cytokines, growth factors, proteases, and signaling proteins. Based on the same technology as the “smaller” version L1000, the L2000 array is the quickest and simplest method to profile extensive protein expression with small sample volume. In this post, we’ll look at the array’s features and technology, as well as the possibility to outsource your profiling project to experts in Europe, particularly for one shot experiments, to save you the time to set up the technology in your lab whilst securing the quality of your data.

Whether you wish to perform protein expression profiling for biomarker validation, are deciphering a disease physio-pathology, are looking for the right target to study the effect of your compounds or keen to check what its mechanism of action may be, it’s not always easy to decide on the best tool to choose. I have selected a few solutions below that may bring some quick answers to these questions, and help you move faster to the next step of your biomarker project: they’re either quick to implement in your own lab or easily outsourced at a reasonable cost in a European partner platform.